<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03149445</url>
  </required_header>
  <id_info>
    <org_study_id>TM002</org_study_id>
    <nct_id>NCT03149445</nct_id>
  </id_info>
  <brief_title>Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)</brief_title>
  <acronym>2016-003694-18</acronym>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Multi-centre Safety and Efficacy Study of Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saniona</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saniona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two-centre, double-blind, placebo-controlled, randomized, and multiple-dose clinical study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two-centre, double-blind, placebo-controlled, randomized, and multiple-dose clinical study.
      Study medication will be administered for 91 days. The study will be conducted in two steps:

        -  Step 1 - 10-15 adult subjects with PWS will be treated.

        -  DSMB review and SUKL review - following the completion of the treatment of the adult
           subjects, unblinded efficacy, safety, PK data as well as all data from the study in
           subjects with type 2 diabetes (TM001) will be reviewed by an independent Data Safety
           Monitoring Board (DSMB) and State Institute for Drug Control (SUKL). Following the
           SUKL's approval the study will proceed to:

        -  Step 2 - 10-15 children with PWS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two-centre, double-blind, placebo-controlled, randomized, and multiple-dose clinical study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline on body weight in subjects with PWS</measure>
    <time_frame>0-91 days</time_frame>
    <description>To examine the effect of co-administration of tesofensine/metoprolol on body weight in subjects with PWS</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Confirmed Genetic Diagnosis of Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>Tesofensine/Metoprolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tesofensine + metoprolol administered once a day, in the morning with a meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tesofensine/Metoprolol placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets matching tesofensine + metoprolol administered once a day, in the morning with meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesofensine/Metoprolol</intervention_name>
    <description>Study medication will be administered for 91 days.</description>
    <arm_group_label>Tesofensine/Metoprolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Study medication will be administered for 91 days.</description>
    <arm_group_label>Tesofensine/Metoprolol placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females

          2. Confirmed genetic diagnosis of Prader-Willi syndrome

          3. Age: Step 1: Adults aged 18-30 b. Step 2: Children aged 12-17

          4. BMI:

               1. Step 1: Adults with â‰¥25 kg/m2

               2. Step 2: Children with a BMI &gt;85th percentile for the same age and sex

          5. Normal BP or well managed hypertension (only if dose of BP medication(s) has been
             stable for &gt;2 months)

          6. Normal lipid profile or well managed dyslipidemia (only if dose of lipid-lowering
             medication(s) has been stable for &gt;2 months)

          7. On stable dose of growth hormone &gt;2 months

        Exclusion Criteria:

          1. Hypersensitivity to tesofensine/metoprolol

          2. Type 1 diabetes

          3. Heart failure NYHA level II or greater, decompensated heart failure

          4. Previous myocardial infarction or stroke

          5. Diagnosis of schizophrenia, bipolar disorder, personality disorder or other DSM-III
             disorders, which in the investigator's opinion will interfere significantly with study
             compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jorgen Drejer, PhD</last_name>
    <phone>+45 20289705</phone>
    <email>jd@saniona.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Motol</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanislava Kolouskova, Dr. med.</last_name>
    </contact>
    <contact_backup>
      <email>stanislava.kolouskova@lfmotol.cuni.cz</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Hyperphagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

